EQL Pharma Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 1/6

EQL Pharma yıllık ortalama 35.3% oranında kazançlarını artırırken, Healthcare sektöründe kazançlar growing at 20% annual. Gelirler growing yılda ortalama 24.9% oranında artmaktadır. EQL Pharma'in özkaynak karlılığı 14% ve net marjı 9%'dir.

Anahtar bilgiler

35.3%

Kazanç büyüme oranı

35.8%

EPS büyüme oranı

Healthcare Sektör Büyümesi8.1%
Gelir büyüme oranı24.9%
Özkaynak getirisi14.0%
Net Marj9.0%
Sonraki Kazanç Güncellemesi06 Nov 2024

Yakın geçmiş performans güncellemeleri

EQL Pharma's (STO:EQL) Shareholders Have More To Worry About Than Only Soft Earnings

Aug 22
EQL Pharma's (STO:EQL) Shareholders Have More To Worry About Than Only Soft Earnings

EQL Pharma's (NGM:EQL) Weak Earnings May Only Reveal A Part Of The Whole Picture

Feb 21
EQL Pharma's (NGM:EQL) Weak Earnings May Only Reveal A Part Of The Whole Picture

Recent updates

Market Participants Recognise EQL Pharma AB (publ)'s (STO:EQL) Earnings Pushing Shares 26% Higher

Oct 29
Market Participants Recognise EQL Pharma AB (publ)'s (STO:EQL) Earnings Pushing Shares 26% Higher

EQL Pharma's (STO:EQL) Shareholders Have More To Worry About Than Only Soft Earnings

Aug 22
EQL Pharma's (STO:EQL) Shareholders Have More To Worry About Than Only Soft Earnings

Here's Why EQL Pharma (STO:EQL) Has A Meaningful Debt Burden

Aug 12
Here's Why EQL Pharma (STO:EQL) Has A Meaningful Debt Burden

EQL Pharma AB (publ)'s (NGM:EQL) P/E Is Still On The Mark Following 30% Share Price Bounce

Jun 13
EQL Pharma AB (publ)'s (NGM:EQL) P/E Is Still On The Mark Following 30% Share Price Bounce

EQL Pharma (NGM:EQL) Is Doing The Right Things To Multiply Its Share Price

May 14
EQL Pharma (NGM:EQL) Is Doing The Right Things To Multiply Its Share Price

EQL Pharma's (NGM:EQL) Weak Earnings May Only Reveal A Part Of The Whole Picture

Feb 21
EQL Pharma's (NGM:EQL) Weak Earnings May Only Reveal A Part Of The Whole Picture

The Trend Of High Returns At EQL Pharma (NGM:EQL) Has Us Very Interested

Jun 28
The Trend Of High Returns At EQL Pharma (NGM:EQL) Has Us Very Interested

With EPS Growth And More, EQL Pharma (NGM:EQL) Makes An Interesting Case

Apr 28
With EPS Growth And More, EQL Pharma (NGM:EQL) Makes An Interesting Case

EQL Pharma AB (publ)'s (NGM:EQL) 26% Jump Shows Its Popularity With Investors

Feb 24
EQL Pharma AB (publ)'s (NGM:EQL) 26% Jump Shows Its Popularity With Investors

EQL Pharma (NGM:EQL) Is Achieving High Returns On Its Capital

Dec 19
EQL Pharma (NGM:EQL) Is Achieving High Returns On Its Capital

Does EQL Pharma (NGM:EQL) Deserve A Spot On Your Watchlist?

Jun 29
Does EQL Pharma (NGM:EQL) Deserve A Spot On Your Watchlist?

Is EQL Pharma (NGM:EQL) Using Too Much Debt?

Apr 29
Is EQL Pharma (NGM:EQL) Using Too Much Debt?

We Think EQL Pharma AB (publ)'s (NGM:EQL) CEO Compensation Looks Fair

Aug 10
We Think EQL Pharma AB (publ)'s (NGM:EQL) CEO Compensation Looks Fair

EQL Pharma (NGM:EQL) Hasn't Managed To Accelerate Its Returns

Jun 07
EQL Pharma (NGM:EQL) Hasn't Managed To Accelerate Its Returns

If You Like EPS Growth Then Check Out EQL Pharma (NGM:EQL) Before It's Too Late

Apr 16
If You Like EPS Growth Then Check Out EQL Pharma (NGM:EQL) Before It's Too Late

How Many EQL Pharma AB (publ) (NGM:EQL) Shares Have Insiders Sold, In The Last Year?

Mar 11
How Many EQL Pharma AB (publ) (NGM:EQL) Shares Have Insiders Sold, In The Last Year?

Are EQL Pharma's (NGM:EQL) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Feb 21
Are EQL Pharma's (NGM:EQL) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Is EQL Pharma AB (publ)'s (NGM:EQL) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Feb 03
Is EQL Pharma AB (publ)'s (NGM:EQL) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

What We Learned About EQL Pharma's (NGM:EQL) CEO Compensation

Jan 16
What We Learned About EQL Pharma's (NGM:EQL) CEO Compensation

Will the Promising Trends At EQL Pharma (NGM:EQL) Continue?

Dec 28
Will the Promising Trends At EQL Pharma (NGM:EQL) Continue?

What Type Of Shareholders Make Up EQL Pharma AB (publ)'s (NGM:EQL) Share Registry?

Dec 11
What Type Of Shareholders Make Up EQL Pharma AB (publ)'s (NGM:EQL) Share Registry?

EQL Pharma (NGM:EQL) Has Rewarded Shareholders With An Exceptional 436% Total Return On Their Investment

Nov 22
EQL Pharma (NGM:EQL) Has Rewarded Shareholders With An Exceptional 436% Total Return On Their Investment

Gelir ve Gider Dağılımı

EQL Pharma nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.


Kazanç ve Gelir Geçmişi

OM:EQL Gelir, gider ve kazançlar (SEK Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
30 Jun 24291267413
31 Mar 24264237112
31 Dec 23246226814
30 Sep 23256286414
30 Jun 23270306314
31 Mar 23260316015
31 Dec 22403335914
30 Sep 22440395611
30 Jun 2241936519
31 Mar 2241032489
31 Dec 21233194110
30 Sep 2114543411
30 Jun 2111723112
31 Mar 21179102812
31 Dec 2017217322
30 Sep 2016316322
30 Jun 2015714322
31 Mar 20723300
31 Dec 19682245
30 Sep 1958-2253
30 Jun 1954-2252
31 Mar 1950-2250
31 Dec 1843-2210
30 Sep 18410200
30 Jun 18350180
31 Mar 1832-1170
31 Dec 17301160
30 Sep 17300150
30 Jun 17260150
31 Mar 17240140
31 Dec 16314150
30 Sep 16295140
30 Jun 16346140
31 Mar 16357140
31 Dec 15294130
30 Sep 15261130
30 Jun 1521-2130
31 Mar 1519-5130
31 Dec 1418-9130
30 Sep 1419-11130
30 Jun 1419-12120
31 Mar 1420-11110
31 Dec 1322-8100

Kaliteli Kazançlar: EQL yüksek düzeyde nakit dışı kazança sahiptir.

Büyüyen Kar Marjı: EQL 'nin mevcut net kar marjları (9%) geçen yılın (11.2%) değerinden daha düşüktür.


Serbest Nakit Akışı ve Kazanç Analizi


Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: EQL son 5 yılda karlı hale geldi ve kazançlarını yıllık 35.3% oranında artırdı.

Büyüme Hızlandırma: EQL 'in son bir yıldır negatif kazanç büyümesi oldu, bu nedenle 5 yıllık ortalamasıyla karşılaştırılamaz.

Kazançlar vs. Sektör: EQL geçtiğimiz yıl negatif kazanç büyümesine ( -13.4% ) sahipti ve bu da onu Healthcare sektör ortalamasıyla ( 16.3% ) karşılaştırmayı zorlaştırıyordu.


Özkaynak Getirisi

Yüksek ROE: EQL 'nin Özsermaye Getirisi ( 14% ) düşük olarak değerlendiriliyor.


Varlık Getirisi


Kullanılan Sermaye Getirisi


Geçmişte güçlü performans gösteren şirketleri keşfedin